Search Results - "D D Bigner"

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study by Schuster, James, Lai, Rose K, Recht, Lawrence D, Reardon, David A, Paleologos, Nina A, Groves, Morris D, Mrugala, Maciej M, Jensen, Randy, Baehring, Joachim M, Sloan, Andrew, Archer, Gary E, Bigner, Darell D, Cruickshank, Scott, Green, Jennifer A, Keler, Tibor, Davis, Thomas A, Heimberger, Amy B, Sampson, John H

“…The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term…”
Get full text

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy by Shao, Huilin, Chung, Jaehoon, Balaj, Leonora, Charest, Alain, Bigner, Darell D, Carter, Bob S, Hochberg, Fred H, Breakefield, Xandra O, Weissleder, Ralph, Lee, Hakho

“…Cancer cells shed large numbers of small, membrane-bound microvesicles (MVs) into the circulation, which have diagnostic potential but have proved difficult to…”
Get full text

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome by Reitman, Zachary J, Jin, Genglin, Karoly, Edward D, Spasojevic, Ivan, Yang, Jian, Kinzler, Kenneth W, He, Yiping, Bigner, Darell D, Vogelstein, Bert, Yan, Hai

“…Point mutations of the NADP⁺-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and…”
Get full text

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients by Reardon, D A, Herndon, J E, Peters, K B, Desjardins, A, Coan, A, Lou, E, Sumrall, A L, Turner, S, Lipp, E S, Sathornsumetee, S, Rich, J N, Sampson, J H, Friedman, A H, Boulton, S T, Bigner, D D, Friedman, H S, Vredenburgh, J J

“…Background: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial…”
Get full text

The integrated landscape of driver genomic alterations in glioblastoma by Frattini, Veronique, Trifonov, Vladimir, Chan, Joseph Minhow, Castano, Angelica, Lia, Marie, Abate, Francesco, Keir, Stephen T, Ji, Alan X, Zoppoli, Pietro, Niola, Francesco, Danussi, Carla, Dolgalev, Igor, Porrati, Paola, Pellegatta, Serena, Heguy, Adriana, Gupta, Gaurav, Pisapia, David J, Canoll, Peter, Bruce, Jeffrey N, McLendon, Roger E, Yan, Hai, Aldape, Ken, Finocchiaro, Gaetano, Mikkelsen, Tom, Privé, Gilbert G, Bigner, Darell D, Lasorella, Anna, Rabadan, Raul, Iavarone, Antonio

“…Anna Lasorella, Raul Rabadan, Antonio Iavarone and colleagues report an integrated analysis of genomic alterations in glioblastoma. They identify and…”
Get full text

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation by Wheeler, S E, Suzuki, S, Thomas, S M, Sen, M, Leeman-Neill, R J, Chiosea, S I, Kuan, C-T, Bigner, D D, Gooding, W E, Lai, S Y, Grandis, J R

“…Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of…”
Get full text

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy by Gromeier, Matthias, Brown, Michael C., Zhang, Gao, Lin, Xiang, Chen, Yeqing, Wei, Zhi, Beaubier, Nike, Yan, Hai, He, Yiping, Desjardins, Annick, Herndon, James E., Varn, Frederick S., Verhaak, Roel G., Zhao, Junfei, Bolognesi, Dani P., Friedman, Allan H., Friedman, Henry S., McSherry, Frances, Muscat, Andrea M., Lipp, Eric S., Nair, Smita K., Khasraw, Mustafa, Peters, Katherine B., Randazzo, Dina, Sampson, John H., McLendon, Roger E., Bigner, Darell D., Ashley, David M.

“…Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10–20% of patients. Here we perform genomic…”
Get full text

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling by Brown, Michael C., Mosaheb, Mubeen M., Mohme, Malte, McKay, Zachary P., Holl, Eda K., Kastan, Jonathan P., Yang, Yuanfan, Beasley, Georgia M., Hwang, E. Shelley, Ashley, David M., Bigner, Darell D., Nair, Smita K., Gromeier, Matthias

“…Activating intra-tumor innate immunity might enhance tumor immune surveillance. Virotherapy is proposed to achieve tumor cell killing, while indirectly…”
Get full text

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma by SAMPSON, John H, HEIMBERGER, Amy B, REARDON, David A, SAWAYA, Raymond, SCHMITTLING, Robert J, WEIMING SHI, VREDENBURGH, James J, BIGNER, Darell D, ARCHER, Gary E, ALDAPE, Kenneth D, FRIEDMAN, Allan H, FRIEDMAN, Henry S, GILBERT, Mark R, HERNDON, James E, MCLENDON, Roger E, MITCHELL, Duane A

“…Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor…”
Get full text

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor by SHIDENG BAO, QIULIAN WU, SATHORNSURNETEE, Sith, YUELING HAO, ZHIZHONG LI, HJELMELAND, Anita B, QING SHI, MCLENDON, Roger E, BIGNER, Darell D, RICH, Jeremy N

“…Malignant gliomas are highly lethal cancers dependent on angiogenesis. Critical tumor subpopulations within gliomas share characteristics with neural stem…”
Get full text

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma by Diplas, Bill H., He, Xujun, Brosnan-Cashman, Jacqueline A., Liu, Heng, Chen, Lee H., Wang, Zhaohui, Moure, Casey J., Killela, Patrick J., Loriaux, Daniel B., Lipp, Eric S., Greer, Paula K., Yang, Rui, Rizzo, Anthony J., Rodriguez, Fausto J., Friedman, Allan H., Friedman, Henry S., Wang, Sizhen, He, Yiping, McLendon, Roger E., Bigner, Darell D., Jiao, Yuchen, Waitkus, Matthew S., Meeker, Alan K., Yan, Hai

“…The majority of glioblastomas can be classified into molecular subgroups based on mutations in the TERT promoter ( TERTp ) and isocitrate dehydrogenase 1 or 2…”
Get full text

Mutant metabolic enzymes are at the origin of gliomas by Yan, Hai, Bigner, Darell D, Velculescu, Victor, Parsons, D Williams

“…Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas…”
Get full text

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme by VREDENBURGH, James J, DESJARDINS, Annick, WAGNER, Melissa, BAILEY, Leighann, BIGNER, Darell D, FRIEDMAN, Allan H, FRIEDMAN, Henry S, HERNDON, James E, MARCELLO, Jennifer, REARDON, David A, QUINN, Jennifer A, RICH, Jeremy N, SATHORNSUMETEE, Sith, GURURANGAN, Sridharan, SAMPSON, John

“…The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of…”
Get full text

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma by VREDENBURGH, James J, DESJARDINS, Annick, BIGNER, Darell D, FRIEDMAN, Allan H, FRIEDMAN, Henry S, HERNDON, James E, DOWELL, Jeannette M, REARDON, David A, QUINN, Jennifer A, RICH, Jeremy N, SATHORNSUMETEE, Sith, GURURANGAN, Sridharan, WAGNER, Melissa

“…Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This…”
Get full text

EGF mutant receptor vIII as a molecular target in cancer therapy by Kuan, C T, Wikstrand, C J, Bigner, D D

Get full text

MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B by Hu, Jing, Sun, Tao, Wang, Hui, Chen, Zhengxin, Wang, Shuai, Yuan, Lifeng, Liu, Tingyu, Li, Hai-Ri, Wang, Pingping, Feng, Yukuan, Wang, Qinhong, McLendon, Roger E., Friedman, Allan H., Keir, Stephen T., Bigner, Darell D., Rathmell, Jeff, Fu, Xiang-dong, Li, Qi-Jing, Wang, Huibo, Wang, Xiao-Fan

“…The hypoxic tumor microenvironment serves as a niche for maintaining the glioma-initiating cells (GICs) that are critical for glioblastoma (GBM) occurrence and…”
Get full text

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity by Mosaheb, Mubeen M., Dobrikova, Elena Y., Brown, Michael C., Yang, Yuanfan, Cable, Jana, Okada, Hideho, Nair, Smita K., Bigner, Darell D., Ashley, David M., Gromeier, Matthias

“…Viruses naturally engage innate immunity, induce antigen presentation, and mediate CD8 T cell priming against foreign antigens. Polioviruses can provide a…”
Get full text

Recent Advances in the Treatment of Malignant Astrocytoma by Reardon, David A, Rich, Jeremy N, Friedman, Henry S, Bigner, Darell D

“…Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration…”
Get full text

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas by Killela, Patrick J, Pirozzi, Christopher J, Healy, Patrick, Reitman, Zachary J, Lipp, Eric, Rasheed, B Ahmed, Yang, Rui, Diplas, Bill H, Wang, Zhaohui, Greer, Paula K, Zhu, Huishan, Wang, Catherine Y, Carpenter, Austin B, Friedman, Henry, Friedman, Allan H, Keir, Stephen T, He, Jie, He, Yiping, McLendon, Roger E, Herndon, 2nd, James E, Yan, Hai, Bigner, Darell D

“…Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant…”
Get full text

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study by Reardon, D A, Desjardins, A, Vredenburgh, J J, Gururangan, S, Sampson, J H, Sathornsumetee, S, McLendon, R E, Herndon, J E, Marcello, J E, Norfleet, J, Friedman, A H, Bigner, D D, Friedman, H S

“…Background: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. Methods: A total of 59…”
Get full text